Navigation Links
InVitria Touts Product Advantages at Cambridge's Cell Culture Conference
Date:9/24/2008

FORT COLLINS, Colo., Sept. 24 /PRNewswire/ -- InVitria (http://www.InVitria.com) addressed attendees at Cambridge Healthtech Institute's 4th Annual "Optimizing Cell Culture Development" Conference on September 15-16 in Boston, Massachusetts and announced its most recent results optimizing cell culture media using its product line of animal free cell culture ingredients. (http://www.healthtech.com/ocb/overview.aspx?c=562)

In a presentation of scientific studies with InVitria's Cellastim and Lacromin, Steve Pettit, Director of InVitria's Cell Culture Group, noted, "The growth and productivity results in CHO cell lines are quite impressive and not achievable with other sources of albumin or transferrin supplements. Cellastim has shown growth and productivity up to 50% better than the next best alternative. Similar impressive results with the use of Lacromin have previously been published by our team(1)," said Pettit.

"We continue to show powerful results of Cellastim and Lacromin in cell culture media for a variety of cell lines including CHO, Hybridoma, Vero and NS0 cells. Since these are well defined supplements, they help our customers achieve both their regulatory and manufacturing goals. These are the only supplements available that not only improve cell culture performance, but do this while maintaining a defined and animal free media," said Scott Deeter, InVitria's President.

About InVitria (http://www.InVitria.com)

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim - Cellastim is a recombinant albumin that is used as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity. Cellastim also has been an effective component in stem cell media and primary cell media.(see http://www.Cellastim.com)

-- Lacromin - Lacromin is recombinant human lactoferrin, a growth factor that also delivers iron similar to transferrin in cell culture media. (see http://www.Lacromin.com)

-- Lysobac - Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher recombinant protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields.(see http://www.Lysobac.com)

(1) Huang et al. Bioactive Recombinant Human Lactoferrin Stimulates Mammalian Cell Growth. Society for InVitro Biology. InVitro Cell Develop. Biology. May 6, 2008.

For more information about the InVitria line of products, please e-mail info@InVitria.com or call 1-800-916-8311.


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitria Sponsors Cambridge Healthtechs Optimizing Cell Culture Development Conference
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. InVitria Expands Sales Team
4. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
5. Gores Legacy of Innovation Extends From Products to Processes
6. Martek is Now the Sole-Source Supplier of ARA for all Infant Formula Products Manufactured by Hochdorf Nutricare
7. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
8. Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment
9. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
10. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
11. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... The effectiveness of a new wound ... trials in the United States. (clinicaltrials.gov : NCT02973893) , To find out more ... your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ and discuss your condition with ...
(Date:9/21/2017)... and London UK (PRWEB) , ... September 21, ... ... DrugDev , a QuintilesIMS company, who enable the world’s most progressive pharma and ... over 2,000 clinical trials at top pharma and biotech events in Q4. , ...
(Date:9/20/2017)... ... ... The award-winning producers behind the American Farmer series proudly ... at helping farmers solve the problem of nitrogen loss. The upcoming episode is ... RFD-TV. Check your local listings for more info. , As a global ...
(Date:9/20/2017)... , ... September 20, 2017 ... ... published findings of a study examining the effects of exoskeleton-assisted walking on ... cord injury (SCI). The article, "Neuromechanical adaptations during a robotic powered exoskeleton ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):